Uremic Pruritus: Interleukin-31 as a Target of Therapy in End Stage Renal Disease Patients | ||
| Zagazig University Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 25 June 2025 | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/zumj.2025.384935.3952 | ||
| Authors | ||
| Alsayed Alnahal1; Hossam Hassan Elmessallamy* 2; Magda Mahrous3; Mohamed Hamed Khater4; Hanaa M Elmaghraby5; Mohammed Attia Abd El-Moniem6 | ||
| 1Internal Medicine, Zagazig University | ||
| 2Internal medicine, faculty of medicine, Zagazig university, Zagazig, Egypt | ||
| 3Internal medicine, faculty of medicine, zagazig university, zagazig, Egypt | ||
| 4Dermatology Department, Faculty of Medicine, Zagazig University, Egypt. | ||
| 5Medical Microbiology, faculty of medicine, Zagazig university, Zagazig, Egypt | ||
| 6Lecturer of Internal Medicine, Faculty of Medicine, Zagazig university, Egypt | ||
| Abstract | ||
| Abstract Background: Uremic pruritus is a prevalent and distressing complication associated with End Stage Renal Disease that can adversely impact quality of life. Uremic pruritus represents one of the skin manifestations seen in End Stage Renal Disease (ESRD). The underlying mechanisms of Uremic pruritus remain incompletely understood; however, it is believed to be driven by multiple factors, including the pruritoceptive theory, local neuropathic processes, the neurogenic theory (which involves dysregulation of the endogenous opioid system), and the immunological theory. Rising serum interleukin-31 level was found in End Stage Renal Disease (ESRD) patients experiencing Uremic pruritus when compared to those without this symptom. Furthermore, interleukin-31 has positive correlation with the intensity of Uremic Pruritus (UP). Various medications have been employed to manage Uremic Pruritus (UP). Treatments such as gabapentin and antihistamines have been effective in alleviating Uremic pruritus (UP) symptoms. Recently, difelikefalin has been introduced as a therapeutic option for Uremic pruritus (UP), demonstrating a notable decrease in the intensity of the condition. Conclusion: The review offers a simplified overview of the pathophysiology of uremic pruritus and its main lines of treatment with their role on reducing pruritus symptoms, It also clarifies the role of interleukin-31 in uremic pruritus and its correlation with severity. The review also suggest the use of interleukin-31 as a novel therapeutic target. | ||
| Keywords | ||
| Uremic pruritus; ESRD; IL-31; Gabapentin; Difelikefalin | ||
|
Statistics Article View: 72 |
||
